Recommandations en onco-urologie 2013 du CCAFU: Cancer du rein

Patard, Jean‐Jacques; Baumert, H.; Bensalah, Karim; Bernhard, Jean-Christophe; Bigot, Pierre; Escudier, Bernard; Grenier, N.; Hétet, Jean-François; Long, Jean-Alexandre; Méjean, Arnaud; Paparel, P.; Richard, Stéphane; Rioux‐Leclercq, Nathalie; Coloby, P.; Soulié, M.

doi:10.1016/s1166-7087(13)70055-1

Cited by 46 publications

(14 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La biopsie est recommandée par les sociétés savantes [1][2][3], mais n'est pas réalisée systématiquement ou non contributive. Dans la méta-analyse de Kunkle et al, 42,8 % des biopsies étaient contributives ou réalisées pour la cryoablation et 17,7 % pour la radiofréquence [10].…”

Section: Discussionunclassified

“…Les sociétés savantes européen-nes (AFU, EAU) précisent dans leurs recommandations que les thérapies ablatives sont réservées aux patients présen-tant des contre-indications chirurgicales [1,2].…”

Section: Place Des Traitements Ablatifs Chez Le Sujet âGé Et/ou Le Suunclassified

“…Ceci doit se faire au maximum avec des éléments objectifs : d'une part, des scores prédictifs de survie compétitive, plusieurs scores ont été évalués [51], et d'autre part, une biopsie de la tumeur qui apparaît indispensable tant avant surveillance qu'avant traitement ablatif. Les concordances entre biopsies et pièces opératoires sont bonnes sur le type histologique, mais encore insuffisantes sur le grade de Führman avec une sensibilité comprise entre 43 et 75 % [1]. La cinétique tumorale semble être également un élément évolutif.…”

Section: Place Des Traitements Ablatifs Chez Le Sujet âGé Et/ou Le Suunclassified

See 2 more Smart Citations

Les traitements ablatifs dans le cancer du rein localisé : revue de la littérature en 2014

Chodez

Fiard

Arnoux

et al. 2015

Progrès en Urologie

Self Cite

View full text Add to dashboard Cite

Section: Discussionunclassified

Section: Place Des Traitements Ablatifs Chez Le Sujet âGé Et/ou Le Suunclassified

See 1 more Smart Citation

Les traitements ablatifs dans le cancer du rein localisé : revue de la littérature en 2014

Chodez

Fiard

Arnoux

et al. 2015

Progrès en Urologie

Self Cite

View full text Add to dashboard Cite

“…The main reported off-target effects (grade >2) with sorafenib include rash/desquamation, hypertension, hand-foot reaction and diarrhea 10,13. It is a possible option in second-line treatment of metastatic RCC 14. Bevacizumab is an antiangiogenic monoclonal antibody targeting isoforms of vascular endothelial growth factor A (VEGF-A) and is the first approved therapeutic agent to specifically target the tumor-associated vessels of solid tumors 15.…”

Section: Introductionmentioning

confidence: 99%

“…Bevacizumab is an antiangiogenic monoclonal antibody targeting isoforms of vascular endothelial growth factor A (VEGF-A) and is the first approved therapeutic agent to specifically target the tumor-associated vessels of solid tumors 15. It is currently recommended in association with interferon in first-line treatment and is mainly given in the case of indolent disease 14,16. As they target ubiquitous molecular pathways, TTs are known to sometimes induce unexpected complications, especially among aged patients 9,13.…”

Section: Introductionmentioning

confidence: 99%

The world of targeted therapies in kidney cancers: pitfalls, tips and tricks

Vallard

Trone

Langrand-Escure

et al. 2017

OTT

View full text Add to dashboard Cite

In the past few years, metastatic renal cell carcinoma prognosis was improved by the development of molecular targeted therapies (TTs). At the metastatic stage, the tolerance to treatment is a major concern, not only because of the challenge of the efficacy/toxicity ratio improvement but also because of the importance of an optimal adherence to oral treatments. The present case series relates the issues of dealing with uncommon and sometimes never described side effects of sunitinib and sorafenib. The first case report deals with grade 3 vomiting during hemodialysis with concurrent administration of sunitinib. The second case is an iterative gout attack induced by sunitinib. The third case presents a grade 3 scalp dysesthesia with sorafenib. The fourth case includes an astonishing efficacy of metronomic (ie, low doses during a long period of time) bevacizumab in monotherapy. Multidisciplinary management and systematic reporting of unexpected efficacies and toxicities are needed to better understand TTs real therapeutic index. Although TTs revolutionized metastatic renal cell cancer prognosis, they also brought about previously unknown side effects. Identification and management of these off-target effects may be tricky, and therefore, comedication must be wisely chosen. As the physiopathology of these side effects is still unclear, multidisciplinary management and systematic reporting of toxicities are essential.

show abstract

Are we ready for day-case partial nephrectomy?

et al. 2015

View full text Add to dashboard Cite

Fast-track and day-case surgeries are gaining more and more importance. Their development was eased by the diffusion of minimal invasive surgical strategies and the consequential morbidity reduction. In the field of kidney cancer, seven cases of ambulatory radical nephrectomy were previously reported in the international literature. Regarding robotic partial nephrectomy (PN), short postoperative pathways resulting in patients' discharge on postoperative day 1 were shown to be safe and feasible. We report our initial experience of robot-assisted PN discharged on postoperative day zero and discuss the criteria for adequate patient selection. Indeed, outpatient PN will obviously not be suitable for all patients, and careful selection will be mandatory. Both specific baseline patient's factors and postoperative events will have to be recognized for the first ones and prevented for the second ones. Safety, patient satisfaction, cost efficiency, and reproducibility will be the key factors to assess and promote day-case PN.

show abstract

Recommandations en onco-urologie 2013 du CCAFU: Cancer du rein

Cited by 46 publications

References 155 publications

Les traitements ablatifs dans le cancer du rein localisé : revue de la littérature en 2014

Les traitements ablatifs dans le cancer du rein localisé : revue de la littérature en 2014

The world of targeted therapies in kidney cancers: pitfalls, tips and tricks

Are we ready for day-case partial nephrectomy?

Contact Info

Product

Resources

About